论文部分内容阅读
为期12周的随机自身对照、开放性研究。30例新诊T2DM患者以重和林M30治疗,分别于治疗0周、4周、8周、12周测定患者HOMA-IR、胰岛β细胞功能、7个时点血糖、(HbA1c)。结果与0周比较,4周、8周及12周时,HOMA-IR呈递近式降低(P<0.05);血糖及糖化血红蛋白水平明显降低(P<0.01);HOMA-β呈递近式增高(P<0.05)。结论新诊T2DM患者应用重和林M30治疗有显著减轻胰岛素抵抗、促进胰岛β细胞功能恢复作用。
A 12-week randomized, self-controlled, open-label study. Thirty patients with newly diagnosed T2DM were treated with Chonghelin M30. The levels of HOMA-IR, islet β-cell function, blood glucose, and HbA1c were measured at 0, 4, 8 and 12 weeks after treatment. Results Compared with 0 week, HOMA-IR showed a decrease (P <0.05) at 4 weeks, 8 weeks and 12 weeks, and the levels of HbA1c and HbA1c decreased significantly (P <0.01) P <0.05). Conclusions Newly diagnosed T2DM patients treated with Chonghelin M30 can significantly reduce insulin resistance and promote the recovery of pancreatic β-cell function.